The transmembrane immunoglobulin and mucin domain (TIM) family was identified more than a decade ago. Although the founding member of the family was first described in a rat model of ischemia-reperfusion injury, much of the recent interest in the TIM family members has focused on their potential roles in immunity. There are now a large number of genetic studies that have investigated the possible association of various TIM1 and TIM3 polymorphisms with different diseases. Here, we review this body of literature, and highlight some of the most interesting studies.
TIM family proteins
The transmembrane immunoglobulin and mucin domain (TIM) family has more often been referred to as the T-cell immunoglobulin and mucin domain family, although we will use the former term because it more accurately reflects the nature of these proteins and their expression patterns. TIM proteins are characterized by an N-terminal Ig domain of the V subset, followed by a mucin-like domain, single transmembrane domain and a cytoplasmic tail of variable length. The human genome contains three TIM genes, which encode the proteins TIM-1, TIM-3 and TIM-4. This is rather different from the situation with mice, for example, which also contain an expressed gene designated Tim2, as well as several apparent pseudogenes. [1] [2] [3] [4] The founding member of the family, which we will refer to as TIM-1, was discovered in 1998 to be upregulated in a rat model of kidney ischemia and thus designated Kim1 (kidney injury molecule 1). 5 During ischemic kidney injury, a soluble form of Kim1/TIM1 is produced, and the detection of Kim1/TIM1 in urine is currently a clinical diagnostic marker for acute kidney injury. [6] [7] [8] Immunological interest in TIMs was piqued in part by a report that mapped the susceptibility of particular mouse strains to develop atopic asthma to a genomic region containing the Tim locus. 9 Importantly, in this genetic linkage analysis, the Tim locus segregated away from the relatively nearby Th2 cytokine locus, which had previously been implicated in susceptibility to atopic asthma. This report also identified the human homolog of Tim-1 as the hepatitis A virus (HAV) receptor (hHAVcr1). Thus, several years earlier, Kaplan et al. 10 described a protein expressed on monkey and human cells that they called HAVcr1, which was identified based on its ability to act as a cellular receptor for HAV. Meanwhile, Kuchroo and colleagues 11 were studying a novel transmembrane protein (Tim-3) that they identified in mice as a relatively specific marker for Th1, but not naive or Th2, T cells. Subsequent studies have defined a role for TIM-3 in the negative regulation of T cell-mediated immune responses, although it is also expressed by cells of the innate arm of the immune systems of mice and humans. 3 The initial report of the TIM family by McIntire et al. noted several polymorphisms each in Tim1 and Tim3, spurring efforts by many groups to search for polymorphisms in human TIM1 and TIM3, as well as their possible connection to various diseases.
TIM-1 and atopic diseases
Atopic diseases, including asthma, atopic dermatitis and allergic rhinitis (AR), are caused by a complex interplay between environmental and genetic factors. As the Tim gene locus was discovered as a major candidate locus for allergy and asthma susceptibility in mice, many epidemiological studies have been conducted to assess the link between atopy and human TIM1 polymorphisms. Given the discovery of the Tim locus in a mouse model of asthma and the emerging role of TIM-1 in the regulation of Th2-cell activation and function, 9 ,12-14 we will first discuss relevant studies that tested TIM1 polymorphisms in specific human populations for possible associations between specific TIM1 variants and atopic diseases. Some of the notable TIM-1 variants in this regard are summarized in Table 1 . These and other variants discussed below are also shown in the context of the TIM-1 gene and protein, in Figure 1 .
The first human study to provide evidence for functional consequences of TIM1 polymorphisms in human disease was reported in 2003. 15 The authors identified several TIM1 variants, including two single amino-acid changes, 195delT and A206T, and a six amino-acid insertion at position 157 (157insMTTTVP) that resulted in lengthening of the TIM-1 mucin domain by 12-14%. More importantly, a cross-sectional study of 375 racially diverse individuals revealed that the 157 insMTTTVP polymorphism, which was present in 63, 46 and 64% of Caucasians, Asians and African Americans in the study, respectively, conferred protection against atopy, but only in HAV seropositive individuals (odds ratio (OR) ¼ 0.257; 95% confidence interval (95% CI) ¼ 0.116-0.570). This result was confirmed by subgroup analysis with Asian and Caucasian participants. It is noteworthy that this is one of the few studies that assessed the role of TIM1 variants in atopy in the context of HAV infection. As a human cellular receptor for HAV, TIM-1 was proposed to interact with HAV for efficient viral binding and uncoating. 16 As the 157insMTTTVP variant of TIM1 is a common allele, this study provided a possible explanation for the inverse relationship between the declining incidence of HAV infection and increased atopy in the industrialized world. In particular, McIntire et al. 15 suggested that individuals with certain TIM1 alleles, such as the 157insMTTTVP variant, are protected against atopy. However, this protective effect may only occur in individuals with previous HAV infection. Subsequent studies have focused on identifying additional TIM1 polymorphisms, with particular emphasis on the mucin domain.
In a series of case-control studies, Chae et al. 17, 18 tested novel polymorphisms in the promoter and coding regions of TIM1 in Korean populations of unrelated asthma and atopic dermatitis patients for association with asthma or atopic dermatitis. Analysis revealed 10 novel TIM1 variants, 5 of which were single-nucleotide polymorphisms (SNPs) in the promoter and coding regions (À1166C4G, À416G4C, À232A4G, 5365C4T and 5529A4G), 1 novel duplication in the promoter (À2278_À2276dupATT) and 3 variations in exon 4 (5383_5397del, 5387_5389insACC and 5509_5511del-CAA). Genotype and allele frequency tests of association suggested that the homozygous sequence of 5509_5511delCAA was associated with asthma (P ¼ 0.011) but not with atopic dermatitis. However, the 5383_5397del variant, also known as 157insMTTTVP, was not significantly associated with either asthma or atopy (P ¼ 0.439; P ¼ 0.063, respectively). Owing to the small sample size, this study was mainly a screening for TIM1 polymorphisms in a Korean population and a preliminary asthma/atopy association survey. The authors subsequently examined the alleles 5383_5397del and 
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J Lee et al 5509_5511delCAA in exon 4 in a larger population involving 200 asthma patients, 112 atopic dermatitis patients and 201 control subjects. 18 Genotype frequency comparisons confirmed an association between 5509_5511delCAA and asthma (P ¼ 0.037). In this larger study, 5383_5397del was found to be strongly associated with atopic dermatitis (P ¼ 0.005). Molecular analyses presented in this study found neither serum IgE levels nor eosinophil counts to be associated with the TIM1 haplotype. The interpretation of these findings was somewhat difficult because it was unclear whether subjects also included patients assessed in a previous study. In addition, there were significant differences in case-control study populations, specifically the relative representation of men and women.
Natural selection tends to act at genetic regions containing functionally important variants. Thus, studies of variations in TIM1/HAVCR1 revealed a large degree of genetic diversity in exon 4 (which encodes the mucin domain), as indicated by the high frequency of nonsynonymous amino-acid substitution and insertion/ deletion variants in this region. 19 Despite the relatively similar patterns of haplotype frequencies in exon 4 of Korean and Japanese populations, the 5383_5397del variant, which was associated with atopy in a Korean population, was not significantly associated with atopic asthma in a Japanese pediatric patient family study. 20 Thus, Noguchi et al. identified 7 polymorphisms in TIM1 from 144 families: À1634A4G; À1606A4C; À1547G4C; À1453G4A; 2 insertion/deletion polymorphisms in exon 4, c469-470insCAATGACAACGACTGTTC; c589-590delGTG and c469-470insTGACGACTGTTCCA termed 'hHAVcr-1* allele 2 and 3', respectively and an intronic variant. With adequate power to detect an OR42, the transmission disequilibrium test indicated that none of the hHAVcr1/TIM1 variant alleles was preferentially transmitted to asthmatic children. In addition, serum IgE levels did not differ by TIM1 haplotype for the variants analyzed. It is worth noting that although HAV infection status was unknown in this subject population, the prevalence of HAV seropositivity in Japan has been reported to be low. 21, 22 Therefore, although polymorphisms in the region encoding the mucin domain of TIM-1 are not linked to atopic diseases in a Japanese population, it is possible that these variations might alter susceptibility to asthma and atopy in other populations in which the prevalence of HAV exposure is higher or in which other genetic factors are at work.
Epidemiological data so far indicate that a connection between TIM1 polymorphisms and atopy was present in some, but not all, populations examined. Atopy and asthma are complex diseases the phenotypes of which may vary during child development and throughout adulthood. As a result, it is important to assess the link between TIM1 polymorphisms and risk factors for asthma and atopy that occur during childhood. In a large cohort study, 23 newborns in Tucson, Arizona, were recruited for a longitudinal study to monitor the development of atopy, asthma and eczema at ages 6, 11 and 16, respectively. In all, 7 TIM1 polymorphisms were identified in 564 subjects. Of these, 5383_5397del was found to have an association with atopy that was strong enough to remain statistically significant after adjustment for multiple comparisons (relative risk (RR) ¼ 1.24; 95% CI ¼ 1.07-1.45, P ¼ 0.005). 5383_5397del was associated with eczema (RR ¼ 1.43; 95% CI ¼ 1.01-2.01, P ¼ 0.004), but the association was not statistically significant after adjustments for multiple comparisons. 5383_5397del was not associated with asthma in this study. This lack of an apparent association may be partly due to the method of obtaining data, as patients were assessed for eczema and asthma through a series of questionnaires, rather than by physician diagnosis, whereas atopy was assessed by skin prick tests to common allergens. Phenotypic manifestations of asthma and allergic diseases can vary throughout life; hence, it is difficult to accurately assess them based solely on questionnaires. In addition, HAV infection status was not obtained from these children; therefore, the authors could not determine whether this factor affected the relationship between 5383_5397ins/del and allergic disease. Nevertheless, this study aimed to remove potential bias through adjustment for multiple comparisons and stratified analysis of polymorphism frequency by ethnicity. Therefore, the increased risk of atopy attributed to the presence of the 5383_5397del variant in this study is likely to be physiologically relevant and independent of ethnicity. In another study of TIM1 polymorphisms and childhood asthma, Wu et al. 24 examined the promoter SNP À232G4A and the 5383_5397ins/del variation in Chinese children with atopic and non-atopic asthma, and found no association between these two variants and the development of asthma. Intriguingly, patients with the heterozygous variant 5383_5397ins/del had significantly higher total serum IgE levels even after adjustment for sex and age (P ¼ 0.0112). As increased serum IgE is associated with an increased risk of asthma, it is possible that this particular TIM1 variant contributes to higher IgE production, thereby enhancing susceptibility to developing childhood asthma in a subset of patients.
Gao et al. 25 conducted a family-based study involving 40 case-parent trios, with a nested case-control study design including 89 asthmatic patients and 94 controls, to assess the association of TIM1 sequence variation, HAV seropositivity and asthma in an African-American population. This study found that 157delMTTTVP was present at a higher frequency in asthmatic individuals than in control subjects (OR ¼ 3.09; 95% CI ¼ 1.05-9.82), but this association was also found in HAV seronegative individuals (OR ¼ 3.00; 95% CI ¼ 0.89-11.6). The association of 157delMTTTVP with asthma was further substantiated by a case-parent trios study. In addition, heterozygous and homozygous sequences carrying the minor T allele in the intronic variant rs2277025 correlated with asthma risk in this African-American population (OR ¼ 2.027; 95% CI ¼ 1.013-4.058 and OR ¼ 2.779; 95% CI ¼ 1.176-6.567, respectively). Haplotype analysis across the TIM1 gene revealed that the T-G-del-G allele was more frequent in asthmatics, whereas the allele C-G-ins-G appeared at a higher frequency in healthy individuals. As 157insMTTTVP has been implicated in protection against atopy in HAV seropositive individuals, 15 Gao et al. determined whether 157ins/delMTTTVP also had a role in HAV infection-related protection in this population. Surprisingly, 157delMTTTVP was linked to asthma in both the family-based and the nested case-control analysis in HAV seronegative individuals. As only two patients with asthma were HAV seropositive, the authors were unable to examine this association in HAV-infected individuals. Hence, this study suggested that 157delMTTTVP was linked to asthma susceptibility independent of HAV status, at least in this population.
As most of the above studies were conducted in relatively developed countries where HAV infection has become quite rare, it is of interest to assess the relationship between TIM1 variants and atopic diseases in places where HAV exposure is still relatively high. According to epidemiological data, as of 1990, China was reported to have a high incidence of HAV infection, with 73.6% of the rural Chinese population having circulating antibodies to HAV. 26 China also experiences occasional outbreaks of hepatitis A, with the most current occurrence in 2006. 27 On the basis of polymorphisms found in linkage studies of TIM1 and allergic diseases, Li et al. 28 examined the insertion/deletion coding polymorphisms, rs45623443 (a.k.a. 5383_5397ins/del) and 5509_5511delCAA in TIM1 exon 4, as well as the SNP IVS 8 þ 9G/A in intron 8, in a case-control study of 352 asthma patients and 309 controls who were unrelated Han Chinese. Genotype and allele frequency tests indicated that these three variants were not significantly associated with asthma, despite the fact that 5383_5397del was linked to atopic dermatitis in a Korean population 18 and to asthma in an HAV seronegative population of African Americans. 25 In addition, 5509_5511delCAA has also been linked to asthma in a Korean population. 17 Although the study by Li et al. suggested that the above polymorphisms were not associated with asthma in a Han Chinese population, the authors did not investigate other polymorphisms in either the promoter or the coding regions of TIM1, where there might exist significant genetic variations unique to this particular Chinese population. In addition, subjects in this study were not serologically tested for HAV exposure; hence, the authors could not properly determine whether there is a physiological connection between HAV exposure and asthma susceptibility in individuals with various TIM1 polymorphisms.
In a separate family-based association study, Wu et al. 29 analyzed 118 case-parent trios and selected 5 polymorphisms in the TIM1 gene for analysis of childhood asthma risk. A pairwise linkage disequilibrium test showed that these polymorphisms were in moderate linkage disequilibrium with each other, but individual polymorphisms, including the 5383_5397ins/del, did not yield significant association with asthma as determined by transmission disequilibrium test and haplotype RR. Nevertheless, when a combination of polymorphisms was assessed, G-A-ins-C-G was overtransmitted to asthmatic children (transmission disequilibrium test P ¼ 0.03; haplotype RR ¼ 1.91; 95% CI ¼ 1.06-3.41), suggesting that this haplotype, with the insertion variant of 5383_5397ins/ del, may confer susceptibility to asthma. Overall, this study indicated that a single polymorphism in this population was not sufficient to confer genetic susceptibility to (or protection from) asthma, but rather a combination of these polymorphisms was required to observe functional effects. As this study was limited to a small number of genotypes, a more comprehensive assessment of TIM1 polymorphisms in a larger population might provide more insight regarding functionally significant SNPs. In addition to asthma and atopic dermatitis, allergic rhinitis (AR) has also been analyzed in several studies of TIM1 polymorphisms. AR is characterized by airway hyperresponsiveness, overproduction of Th2 cytokines and influx of eosinophils in the nasal mucosa. Upon comparing two TIM1 SNPs in the promoter region, À416G4C and À1454G4A, in healthy controls and AR patients, Mou et al. found that the CC genotype of À416G4C and the AA genotype of À1454G4A were significantly associated with development of AR (OR ¼ 2.567, 95% CI ¼ 1.151-3.012; OR ¼ 5.234; 95% CI ¼ 2.339-6.571, respectively); these associations were statistically significant even after Bonferroni's correction and adjustment for sex and age. 30 Moreover, both SNPs were associated with significantly higher allergen-specific serum IgE but not total serum IgE. The authors concluded that À416G4C and À1454G4A in the TIM1 promoter region may be associated with AR in a Han Chinese population, a phenomenon that was not observed in either Korean or Japanese patients with asthma and atopic disease. However, this study did not assess whether these SNPs affect mRNA expression level of TIM1, which could influence Th2 responses observed in AR. The 5383_5397ins/del and 5509_5511delCAA variations in the mucin domain of TIM-1 failed to exhibit any association with AR, whereas these variations were implicated in atopic dermatitis and asthma, respectively, in a Korean population. 18 Overall, this study agrees with previous reports examining Han Chinese populations in both case-control and family-based studies, suggesting that atopic and asthma susceptibility are not linked to individual variations in the mucin domain of TIM-1. 29 This in part can be explained by the relatively low heterozygosity of exon 4 in Chinese populations. 19 Thus, results from various populations, despite limitations in study design, suggest that the role of TIM-1 in establishing Th2-biased responses may be influenced at least in part by factors that differ by ethnicity.
Despite the intensive search for TIM1 haplotype association with allergy and asthma, few studies have offered insights into the potential mechanism of this association. Xu et al. 31 reported that TIM1 mRNA expression was upregulated along with the Th2 transcription factor GATA-3, thereby suggesting that TIM-1 is involved in differentiation of Th2 T cells. McIntire et al. 16 proposed that the longer TIM-1 mucin domain encoded by 157insMTTTVP allows for more efficient viral uncoating and entry, leading to either inhibition of or diversion from the Th2 responses seen in atopic diseases. On the other hand, by constructing major TIM1 haplotypes with various SNPs and exon 4 variations identified in a Spanish Caucasian population, GarciaLozano et al. 32 found that 157insMTTTVP belonged to a low mRNA expression haplotype. Thus, lower expression of TIM-1 may also lead to reduced Th2 responses, as suggested by McIntire et al. Recent studies of acute liver failure in an Argentinean population of children infected with HAV 33 also provided supporting evidence to the above proposed model by McIntire et al. 15 Patients with severe liver failure had an increased tendency to possess the 157insMTTTVP variant or the 'long form' of TIM-1. Using fusion proteins consisting of various forms of TIM-1, it was found that the 'long form' bound HAV most efficiently. When expressed on NKT cells, this TIM-1 variant was associated with greater cytotoxicity for HAVinfected cells, which was abolished by an anti-TIM1 antibody. 33 It has become increasingly evident that atopic diseases like asthma are quite heterogeneous, with contributions from both the innate and adaptive arms of the immune system. 33 The variants of TIM-1 and their differential effects in various populations reflects the involvement of a viral receptor that has been shaped by selective pressure of natural selection to become a relevant modulator of allergic responses in the absence of viral infection. Although the significance of previous HAV infection in the susceptibility to atopy conferred by TIM1 polymorphisms is still debatable, recent studies raise the questions of whether HAV infection needs to occur during childhood and whether HAV vaccination can produce the same effects as natural infection.
TIM-1 and RA
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the synovial membrane, cartilage and bone, leading to joint destruction. RA has been considered a Th1-driven autoimmune disorder, but the importance of Th17 cells has been emerging. In established disease, the synovial fluid of RA patients contains relatively high levels of pro-inflammatory cytokines such as tumor necrosis factor-a, interleukin (IL)-6, IL-12 and IL-23, but relatively low amounts of IL-4 and IL-13. As discussed above, Chae et al. 17, 18 studied the association of multiple SNPs and variations in the promoter and coding regions of the TIM1 gene with allergic disease in a Korean population. In a separate study, Chae et al. 34 assessed the association of these variants with RA. By comparing the genotype and allele frequency between RA patients and controls, these investigators found that the homozygous sequence of 5383_5397del was significantly associated with reduced susceptibility to RA (OR ¼ 0.25; 95% CI ¼ 0.09-0.68). In addition, the homozygosity of 5509_5511delCAA was significantly linked to susceptibility to RA (OR ¼ 5.15; 95% CI ¼ 0.70-15.65). However, these two variants did not correlate with levels of C-reactive protein and rheumatoid factor, which are characteristic of RA. It is worth noting that the homozygous variation sequence of 5383_5397del was significantly associated with susceptibility to atopy in their previous study. 18 Furthermore, the homozygous variation sequence of 5509_5511del-CAA is underrepresented in asthmatic patients than in healthy controls. Results from these studies indicated that variations in exon 4 may be linked to a tendency to develop imbalanced Th1 or Th2 responses. Nevertheless, it remains to be determined whether variations in exon 4 of the TIM1 gene are associated with differences in TIM-1 expression or expression and, in turn, Th1/Th2 differentiation.
Chae et al. 35 subsequently assessed the relationship between polymorphisms in the TIM1 promoter, exon 1, intron 1 and susceptibility to RA. By combining data from newly recruited RA and control individuals with those in the previous RA study, 34 the authors showed that only the À1637A4G polymorphism in the promoter region was associated with development of RA. In particular, the G allele was present at a higher frequency in RA patients (OR ¼ 1.85; 95% CI ¼ 1.29-2.66). According to data not shown, this association was not affected by gender, likely because RA patients in this study were predominantly female. Haplotypes generated using the À1637A4G, À416G4C and À232A4G promoter polymorphisms showed that the A-C-G and A-C-A haplotypes were present at a significantly higher frequency in control patients than in RA patients (P ¼ 0.001 and P ¼ 0.023, respectively). However, a more robust connection of À1637A4G with RA could not be made as this SNP was not associated with C-reactive protein and rheumatoid factor levels. Overall, this study provided evidence that promoter polymorphisms may influence susceptibility to developing RA, but did not directly address whether levels of TIM-1 protein expression are affected by these polymorphisms.
TIM-1 and MS
Multiple sclerosis is a T cell-mediated autoimmune disease of the central nervous system. Khademi et al. 36 reported that TIM1 mRNA expression was significantly upregulated in cerebrospinal fluid mononuclear cells of patients with multiple sclerosis (MS), compared with control patients. Curiously, upregulation of TIM1 message was also linked to lower interferon-g levels and the inactive phase of MS, suggesting that TIM-1 expression may be a regulator or marker of remission. To determine whether the TIM1 polymorphisms were indeed associated with MS in a Western Austrian population, Grabmer et al. 37 developed a PCR with sequence-specific priming approach to map the SNPs in the TIM1 promoter and coding regions. Fine mapping revealed five SNPs in the promoter, two SNPs in exon 4, two SNPs in intron 4 and one SNP in intron 7. However, there was no significant association between disease state and any of the above SNPs after Bonferroni's correction for multiple comparisons. The authors proposed that failure to detect any significant difference might be due to the relatively low statistical power of 30% to detect an OR of 2.51. Hence, a larger sample of MS patients would likely be necessary to accurately pinpoint small differences between MS and control.
TIM-1 and SLE
Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease, characterized by tissue damage, due to deposition of immune complexes in various organs, including the kidney. Lupus nephritis is a major contributor to the mortality of lupus patients, and has been associated with dysregulation of either Th1 or Th2 responses. 34, 38 On the basis of its potential influence on Th1/Th2 regulation, the TIM1 gene was investigated for its association with development of SLE. Wang et al. 39 examined TIM-1 expression on peripheral blood mononuclear cells (PBMC) of 19 SLE patients and found a significant increase in TIM-1 expression in these patients, compared with sex-matched healthy controls (P ¼ 0.021). In addition, production of IL-10 was upregulated in these patients and was also positively correlated with TIM-1 expression (r s ¼ 0.4188, P ¼ 0.0372). However, there was only a marginal negative correlation between expression of TIM-1 and active SLE (r s ¼ 0.4544, P ¼ 0.0498). In another study linking TIM1 polymorphisms to the progression of SLE, Li et al. 40 examined the genotype and allele frequency of the SNPs rs12522248 (A4G) in exon 4 and rs1501909 (C4A) in intron 4 from SLE patients and healthy controls. This study also assessed the frequency of these polymorphisms in SLE patients with and without lupus nephritis , according to clinical disease activity. However, there was no association between these two SNPs and SLE after adjustment for sex and age, possibly due to low statistical power to detect a true-positive association (o15%). Therefore, it is possible that other TIM1 variants in this region and in the promoter may be associated with SLE when larger samples from different populations are examined.
TIM-1 and cerebral malaria
Cerebral malaria is a major cause of death after infection by the malaria parasite Plasmodium falciparum. Inflammatory cytokines such as interferon-g produced by Th1 cells are essential for elimination of the parasites, but the same cytokines are also involved in the development of cerebral malaria. 41 Therefore, Nuchnoi et al.
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assessed whether TIM1 polymorphisms could potentially regulate the balance between Th1 and Th2 cytokine production. In this study, 478 Thai malaria patients were subdivided into mild, non-cerebral and cerebral malaria. The three promoter SNPs À1637G4A, À1549G4C and À1454G4A maintained significant difference in allele frequency between mild and cerebral malaria even after Bonferroni's correction (all P ¼ 0.0009). In addition, a TIM1 haplotype that comprised À1637A, À1549C and À1454A was significantly associated with protection against cerebral malaria (OR ¼ 0.41; 95% CI ¼ 0.24-0.71).
As the above promoter SNPs were in complete linkage disequilibrium (r 2 ¼ 1), promoter haplotypes were constructed to determine the functional effect of these polymorphisms on TIM1 transcription. The haplotype H2 (À1637A, À1549C, À1454A) was found to confer a TIM1 mRNA transcription level that was 3.9 times higher than that of haplotype H1 (À1637G, À1549G, À1454G). However, due to the complete linkage disequilibrium between these SNPs, this study was not able to identify the primary polymorphism responsible for protection. These results demonstrated that the TIM1 promoter haplotype consisting of À1637A, À1549C, À1454A was associated with protection against cerebral malaria, potentially due to higher TIM-1 expression and consequently higher Th2 cytokine (and corresponding lower Th1 cytokine) production. Therefore, it would be interesting to compare TIM-1 expression or the levels of Th1 and Th2 cytokines in mild versus cerebral malaria patients.
TIM-1 and HIV/AIDS
Th1 cells are essential for immune responses against intracellular infection caused by viruses and parasites. Wichukchinda et al. 43 investigated the association of six TIM1 haplotypes with progression of HIV (human immunodeficiency virus)/AIDS (acquired immunodeficiency symptoms) in a population of HIV-1-infected Thai females. The D3-A haplotype was marginally associated with higher CD4 þ T-cell count (P ¼ 0.0615) compared with other haplotypes. D3-A carriers also had a lower rate of HIV-1-related symptoms, which was not significant after correction for multiple comparisons. On the other hand, the haplotype D3-C was associated with the opposite phenotypes to D3-A, such as lower CD4 þ T-cell count (P ¼ 0.07) and a higher rate of HIV-1-related symptoms (P ¼ 0.05). Given the potential positive effect of D3-A on HIV-1 progression, the authors further examined the relationship between D3-A and mortality. Indeed, D3-A carriers had significantly higher survival (P ¼ 0.044) than did non-D3-A patients, even after adjustment for the antiviral treatment that was started by some patients during the course of this study (P ¼ 0.019). Consistent with a higher survival rate, D3-A patients had lower risk of death in the untreated period compared with others (hazard ratio ¼ 0.51; 95% CI ¼ 0.29-0.90). Importantly, the association was maintained after adjustment for age and plasma viral load, but not after adjustment for CD4 cell count baseline, suggesting that the protective effects of D3-A haplotype may be connected to CD4 cell count. This group also analyzed the association of the promoter SNPs À1637G4A and À1549G4C with TIM-1 expression, but could not detect any difference in TIM-1 expression. 43 This absence of association is contrary to a previous study that observed higher TIM-1 mRNA transcription with the promoter haplotype À1637A/ À1549C. 42 However, a B-cell line carrying the D3-A haplotype had significantly higher TIM-1 transcript levels than did the non-D3-A cell lines (P ¼ 0.0421). Thus, it would be interesting to compare TIM-1 expression on CD4T cells of HIV-1-infected patients and healthy controls.
TIM-3 and allergic diseases
Transmembrane immunoglobulin and mucin domain-3 is preferentially expressed on Th1 cells versus Th2 cells and known to negatively regulate Th1T-cell responses. However, TIM-3 may also be able to affect Th2-driven allergic diseases by indirectly modulating the balance between Th1-and Th2-type responses. Administration of anti-Tim-3 antibody decreased the production of Th2 cytokines and infiltration of eosinophils and Th2T cells, preventing allergen-induced airway inflammation in a mouse model of asthma. 44 Tim-3 is constitutively expressed by mast cells and Tim-3 polyclonal antibody treatment enhanced production of Th2 cytokines such as IL-4, IL-6 and IL-13 from mast cells, without inducing degranulation. 45 Several genetic studies on TIM-3 polymorphisms have suggested that TIM-3 is involved in the susceptibility to Th2-driven allergic diseases. Some of the notable TIM-3 variants in this regard are summarized in Table 2 . These and other variants discussed below are also shown in the context of the TIM-3 gene and protein, in Figure 2 . Chae et al. investigated frequencies of TIM3 polymorphisms in asthma and AR patients from a Korean population (n ¼ 254, 133 males and 121 females). The À574T allele was found only in asthma and rhinitis patients at the frequency of 1 and 1.5%, respectively, whereas all healthy controls carried the G allele only. The minor T allele of 4259T4G was found more frequently in rhinitis patients, but not in asthma patients. 46 However, although these polymorphisms correlated with symptoms of allergic asthma or rhinitis, a significant correlation with serum IgE level or blood eosinophil counts was not seen. Graves et al. 23 investigated a possible correlation between atopic diseases in children from White or Hispanic parents (n ¼ 1088, DNA sample from 568 subjects) and three polymorphisms À882C4T, 4259T4G and 22713A4G. None of the TIM-3 polymorphisms tested seemed to be associated with asthma in children. 22713A4G and À882C4T were shown to be associated with atopic dermatitis, but 4259T4G (which was associated with asthma in a Korean population) did not seem to be associated with either atopic dermatitis or asthma in the study by Graves et al. This study has a limitation in that asthma and eczema were assessed by questionnaire, rather than by physician's diagnosis and, in spite of adjustment, there is the possibility of falsepositive results from multiple comparisons. On the contrary, two other studies on children-parent trios did not find evidence of an association of polymorphisms of TIM-3 with allergic diseases. Gao et al. 25 studied the two intronic polymorphisms rs11134551A4G and rs11742259 C4T, and a novel polymorphism in the 3 0 -untranslated region of TIM3 in an African-American population. In this case-control study, neither genotypic, haplotypic nor family-based transmission analysis found an increased risk of asthma with these TIM-3 variants. Another study conducted on Chinese children-parents trios, using transmission disequilibrium test and haplotype RR analysis for single TIM-3 polymorphisms, could not find evidence of an effect of TIM-3 polymorphisms on asthma susceptibility. However, haplotype analysis for the combination of three TIM-3 polymorphisms revealed that the G-G-G haplotype for rs10053538G4T, rs13170556A4G and rs9313441G4A was undertransmitted to asthmatic children. 29 As each study investigated the effect of different polymorphisms on allergic diseases, it may be too early to generalize the consequences of TIM3 polymorphisms for allergic asthma and rhinitis. Thus, TIM-3 is expressed on-and negatively regulates-Th1 cells, and treatment with an agonistic antibody to TIM-3 induces Th2 cytokine production in mast cells. The polymorphisms of TIM-3 associated with Th2-mediated diseases may be due to indirect effects of skewing the Th1/Th2 balance towards Th2. However, it has not been investigated whether variations within the coding or non-coding regions of Tim-3 lead to increased Tim-3 protein expression, stability or function.
TIM-3 and SLE
Wang et al. 39 demonstrated the association of TIM genotype with SLE. Although significantly increased TIM-1 expression was found in peripheral blood mononuclear cells isolated from SLE patients, TIM-3 expression levels were not statistically different. An increase in IL-10 production was observed with peripheral blood mononuclear cells from SLE patients, accompanied by a corresponding decrease in interferon-g. These findings suggest that skewing of the Th1/Th2 balance towards Th2 by the TIM-3-galectin-9 interaction contributes to SLE pathogenesis. Recently, the relationship of two TIM3 polymorphisms rs9313439 (22813 C4G, 3 0 -untranslated region) and rs10515746 (À574G4T) to SLE was explored. Li et al. 40 compared frequencies of TIM3 polymorphisms in Chinese SLE patients without a history of atopic diseases (172 female and 30 male) and sex-matched healthy controls. Neither genotype nor allele frequency analysis found differences in the frequency of TIM-3 variants between patients with SLE and healthy controls. These investigators also compared genotype and allele frequencies between patients with active and inactive disease (n ¼ 94 and n ¼ 105, respectively), subgrouped according to the SLE disease activity index, and again no significant difference was observed. 40 
TIM-3 and RA
It has been suggested that TIM-3 has a protective role in RA. Thus, galectin-9 administration reduced pro-inflammatory Th1 and Th17 cytokine levels in joints and Th1 cytokine production in splenocytes, resulting in suppressed collagen-induced arthritis (CIA) symptoms in mice. 47 TIM-3 expression was upregulated in peripheral monocytes and T cells, and synovial tissue in RA patients. In addition, TIM-3 expression on peripheral blood mononuclear cells, T cells and NKT cells was inversely correlated with plasma tumor necrosis factor-a levels and disease severity. 48, 49 Chae et al. 50 investigated genotype and allele frequencies of three TIM-3 polymorphisms in RA patients. With 295 Korean RA patients (43 males, 253 females, mean age ¼ 38.7 years), these investigators showed that À574G4T and 4259T4G were associated with RA. The minor allele of À574T4G was found only in RA patients (P ¼ 0.001) and the minor allele of 4259G4T was present at significantly higher frequency in RA patients than in healthy controls (P ¼ 0.003). A possible correlation between C-reactive protein and rheumatoid factor levels and the three TIM3 polymorphisms in RA patients was examined. However, no significant differences by genotype were observed. The positive correlation found between RA and TIM-3 polymorphisms À574G4T and 4259T4G may seem contradictory to the study conducted by the same group showing that the same variants are associated with Th2-type allergic diseases. 46 Moreover, Tim-3 ligation and blocking were protective in mouse models of autoimmune arthritis and allergen-induced airway inflammation, respectively. 47, 51 A cohort study using a large population reported that the presence of the Th1-type disease RA does not lower the susceptibility to the Th2-dominant disease asthma, but the incidence of asthma was higher in children with RA than in children without RA. 52 Recently, another study conducted on Korean RA patients (41 males, 325 females, mean age 51 years, 389 healthy controls) investigated 5 polymorphisms, including À574G4T (rs10515746) and 4259T4G (rs1036199). 53 The minor allele frequency of À574G4T was higher in RA patients (P ¼ 0.023), but 4259T4G was not. This study also examined the frequency of rs35960726, located in exon2, the minor allele frequency of which was significantly elevated in RA patients (Po0.001). After stratification for shared epitope (SE) status (with SE ¼ 107 and without SE ¼ 58) both À574G4T and rs35960726 were significantly associated with RA, both in patients with SE (P ¼ 0.006 and Po0.001) and without SE (P ¼ 0.015 and P ¼ 0.001). A significant association of 4259T4G frequency with the disease was found in RA patients with SE, but not in those without SE.
Summary
As detailed here, a large number of studies have now examined the possible association of TIM variants with various diseases. The greatest body of literature thus far has focused on a possible role for TIM1 or TIM3 polymorphisms in susceptibility to atopic disease, particularly asthma. However, most of these studies fail to take into account HAV infection status, which certainly seems to be relevant in the case of studies on TIM-1 10, 15 and perhaps even for TIM-3 as well. 54 Furthermore, it is important to keep in mind that in the initial study that identified the entire Tim locus in mice, as a possible controller of asthma and atopy susceptibility, polymorphisms in the coding regions of both Tim-1 and Tim-3 were described. 9 In addition, the TIM genes are linked, something, which is not taken into account in all studies. One exception is the work by Graves et al., 23 discussed above. It will also be important in the future to obtain more objective data on the disease status of subjects, as many of the previous studies relied on questionnaires, rather than laboratory tests. Finally, there is a need for more thorough mechanistic study of the various TIM polymorphisms that have been implicated in disease susceptibility. Thus, there is a need to study how TIM protein variants differ in not only HAV binding but also interactions with soluble or cell-bound ligands, and how these differences affect intracellular signaling pathways that control leukocyte function.
